ABSTRACT
BACKGROUND: Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. OBJECTIVES: To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV. METHODS: This was an independently conducted post hoc analysis of the moderate-to-severe PV subset enrolled in the Ritux 3 study. Patients were randomized to rituximab plus 0·5 or 1·0 mg kg-1 per day prednisone tapered over 3 or 6 months, or 1·0 or 1·5 mg kg-1 per day prednisone alone tapered over 12 or 18 months, respectively (according to disease severity). The primary end point was complete remission at month 24 without CS (CRoff) for ≥ 2 months, and 24-month efficacy and safety results were also reported. RESULTS: At month 24, 34 of 38 patients (90%) on rituximab plus prednisone achieved CRoff ≥ 2 months vs. 10 of 36 patients (28%) on prednisone alone. Median total cumulative prednisone dose was 5800 mg in the rituximab plus prednisone arm vs. 20 520 mg for prednisone alone. Eight of 36 patients (22%) who received prednisone alone withdrew from treatment owing to AEs; one rituximab-plus-prednisone patient withdrew due to pregnancy. Overall, 24 of 36 patients (67%) on prednisone alone experienced a grade 3/4 CS-related AE vs. 13 of 38 patients (34%) on rituximab plus prednisone. CONCLUSIONS: In patients with moderate-to-severe PV, rituximab plus short-term prednisone was more effective than prednisone alone. Patients treated with rituximab had less CS exposure and were less likely to experience severe or life-threatening CS-related AEs. What's already known about this topic? Pemphigus vulgaris (PV) is the most common type of pemphigus. Corticosteroids, a standard first-line treatment for PV, have significant side-effects. Although their effects are unproven, adjuvant corticosteroid-sparing agents are routinely used to minimize steroid exposure and corticosteroid-related side-effects. There is evidence that the anti-CD20 antibody rituximab is effective in the treatment of patients with severe recalcitrant pemphigus and in patients with newly diagnosed pemphigus. What does this study add? This study provides a more detailed analysis of patients with PV enrolled in an investigator-initiated trial. Rituximab plus prednisone had a steroid-sparing effect and more patients achieved complete remission off prednisone. Fewer patients experienced grade 3 or grade 4 steroid-related adverse events than those on prednisone alone. This collaboration between academia and industry, utilizing independent post hoc analyses, led to regulatory authority approvals of rituximab in moderate-to-severe PV.
Subject(s)
Pemphigus , Humans , Immunologic Factors/adverse effects , Immunosuppressive Agents/adverse effects , Pemphigus/drug therapy , Prednisone , Rituximab/adverse effects , Treatment OutcomeSubject(s)
Photosensitivity Disorders/diagnosis , Dermatology/methods , France , Health Care Surveys , Humans , Societies, MedicalABSTRACT
BACKGROUND: Methotrexate (MTX) is a major systemic treatment for moderate to severe plaque psoriasis. A randomized trial has recently been published evaluating a single weekly dosage (17.5mg), but few prospective real-life data are available. The main objective of this study was to prospectively evaluate the efficacy of MTX in real-life. The secondary objectives were to evaluate predictive parameters for treatment efficacy and the frequency of adverse events. PATIENTS AND METHODS: A prospective cohort involving consecutive at in 25 centres belonging to GEM RESOPSO included all adults with plaque psoriasis in whom MTX treatment was initiated. The efficacy criterion was achievement of PASI 75 at week (W) 12/16. The impact of demographic data, psoriasis characteristics (duration, topography, rheumatism), dosage (W12/16 dosage, cumulative dose after 4 weeks), and mode of administration (subcutaneous vs. oral, concomitant use of folic acid) on efficacy was evaluated. Intention-to-treat (ITT),per protocol (PP), and multivariate analyses were performed. RESULTS: Two hundred and fifty-six patients (F/M: 105/151; mean age: 45.0 years; rheumatism: 12.6%) with plaque psoriasis were included. 99 patients were not analysed at W12/16 (16 because of inefficacy, 16 because of intolerance, 56 were lost to follow-up or had data missing). PASI 75 was achieved in 98 patients, with efficacy of 38.3% in the ITT analysis and 58.3% in the PP analysis. In the ITT analysis, absence of previous use of cyclosporine (P=0.01) and a cumulative dose of MTX>60mg after 4 weeks (P<0.0001) were associated with higher PASI 75 rates. In the PP analysis, only absence of previous use of cyclosporine (P=0.0009) was associated with a better PASI 75 results. There was no association between PASI 75 and patient characteristics (including body mass index), clinical aspects of psoriasis, route of administration, combination with folic acid, or W12/16 dose. Adverse events were reported by 34.8% of patients. These consisted mainly of digestive disorders (nausea, abdominal pain), asthenia and moderate hepatic cytolysis. The frequency of adverse events was correlated with methotrexate dosage. DISCUSSION: The efficacy of MTX in plaque psoriasis in this real-life study of 256 patients is consistent with the data in the literature, including the recently published randomized trial (41% PASI 75). This rate was unaffected by patient weight, route of administration and combined use of folic acid. Absence of previous use of cyclosporine appears to be associated with better efficacy although there is no clear explanation for this. The initial dosage (high dose in the first month) appears to be associated with superior efficacy for W12/W16.
Subject(s)
Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Adult , Cyclosporine/therapeutic use , Dermatologic Agents/adverse effects , Female , Folic Acid/therapeutic use , France , Humans , Male , Methotrexate/adverse effects , Methotrexate/therapeutic use , Middle Aged , Multivariate Analysis , Prospective Studies , Treatment OutcomeSubject(s)
Dermatology/methods , Psoriasis/diagnosis , Quality of Life , Sickness Impact Profile , Adult , Female , Humans , Male , Middle Aged , Psoriasis/psychology , Severity of Illness IndexABSTRACT
BACKGROUND: The development of vitiligo during treatment with biological agents is an unusual event and only a few isolated cases have been reported. OBJECTIVES: To describe the clinical characteristics and evolution of patients developing new-onset vitiligo following initiation of a biological agent for chronic inflammatory disease; and also to report the clinical course of pre-existing vitiligo under biological therapy. METHODS: This nationwide multicentre, retrospective study, carried out between July 2013 and January 2015, describes the characteristics of a large series of 18 patients (psoriasis N = 8, inflammatory rheumatic diseases N = 8, ulcerative colitis N = 1, uveitis N = 1) who developed new-onset vitiligo while receiving a biological agent. RESULTS: TNFα inhibitors were the most common biological agent involved (13/18) while anti-IL-12/23 and anti-IL-17 agents or abatacept were less common (4/18 and 1/18 respectively). Mean duration of biological agent exposure before vitiligo onset was 13.9 ± 16.5 months. Outcome was favourable for most patients (15/17) while maintaining the biological agent. Data were also collected for 18 patients (psoriasis N = 5, inflammatory rheumatic diseases N = 10, inflammatory bowel diseases N = 2, SAPHO N = 1) who had pre-existing vitiligo when treatment with a biological agent started (TNFα inhibitors N = 15, ustekinumab N = 1, rituximab N = 1, tocilizumab N = 1). Vitiligo progressed in seven patients and was stable or improved in eight cases. CONCLUSION: Vitiligo may thus emerge and/or progress during treatment with various biological agents, mainly TNFα inhibitors and could be a new paradoxical skin reaction. De novo vitiligo displays a favourable outcome when maintaining the biological agent, whereas the prognosis seems worse in cases of pre-existing vitiligo.
Subject(s)
Inflammation/pathology , Vitiligo/pathology , Adolescent , Adult , Aged , Chronic Disease , Disease Progression , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: Skin patch-tests in dermatology-allergology practice require good preparation. To this end, the dermatology-allergology group of the French Society of Dermatology introduced an information notice informing patients about patch testing procedures. The aim of this study was to evaluate the utility and understanding of the notice. PATIENTS AND METHODS: The information notice was sent out to patients before testing. On the day of the test, a questionnaire was submitted to patients to evaluate their comprehension of the notice. Another questionnaire was submitted simultaneously to the dermatology-allergology practitioner to evaluate whether the patient had complied with the guidelines given in the information notice. Paired questionnaires were analyzed for this study. RESULTS: Eight dermatology-allergology hospital departments participated in the study and collected 921 paired questionnaires over a period of 18months. Among the vast majority (96.2%) of patients who had read the information notice, most found it useful (98.8%), easy to read (97.4%), and appropriate (91.5%). Ten percent of patients had difficulty understanding. CONCLUSION: This study shows that the information notice was clear and explicit for the immense majority of patients. Thanks to the feedback of a number of patients, the information notice was further improved to enhance patient understanding.
Subject(s)
Patch Tests , Patient Education as Topic , Comprehension , Humans , Patient Compliance , Prospective Studies , Surveys and QuestionnairesABSTRACT
BACKGROUND: Merkel cell polyomavirus (MCPyV) is the main aetiological agent of Merkel cell carcinoma (MCC). Serum antibodies against the major MCPyV capsid protein (VP1) are detected in the general population, whereas antibodies against MCPyV oncoproteins (T antigens) have been reported specifically in patients with MCC. OBJECTIVES: The primary aim was to assess whether detection of serum antibodies against MCPyV proteins at baseline was associated with disease outcome in patients with MCC. The secondary aim was to establish whether evolution of these antibodies during follow-up was associated with the course of the disease. METHODS: Serum T-antigen and VP1 antibodies were assessed by enzyme-linked immunosorbent assay using recombinant proteins in a cohort of 143 patients with MCC, including 84 patients with serum samples available at baseline. RESULTS: Low titres of VP1 antibodies at baseline (< 10 000) were significantly and independently associated with increased risk of recurrence [hazard ratio (HR) 2·71, 95% confidence interval (CI) 1·13-6·53, P = 0·026] and death (HR 3·74, 95% CI 1·53-9·18, P = 0·004), whereas T-antigen antibodies were not found to be associated with outcome. VP1 antibodies did not differ between patients in remission and those with recurrence or progression during follow-up. However, T-antigen antibodies were more frequently detected in patients with recurrence or progression at 12 months (P = 0·020) and 24 months (P = 0·016) after diagnosis. CONCLUSIONS: VP1 antibodies constitute a prognostic marker at baseline, whereas T-antigen antibodies constitute a marker of disease recurrence or progression if detected > 12 months after diagnosis.
Subject(s)
Antigens, Viral, Tumor/blood , Biomarkers, Tumor/blood , Capsid Proteins/blood , Carcinoma, Merkel Cell/immunology , Skin Neoplasms/immunology , Adult , Aged , Aged, 80 and over , Carcinoma, Merkel Cell/mortality , Enzyme-Linked Immunosorbent Assay , Female , Humans , Kaplan-Meier Estimate , Male , Merkel cell polyomavirus/immunology , Middle Aged , Neoplasm Recurrence, Local/immunology , Neoplasm Recurrence, Local/mortality , Polyomavirus Infections/immunology , Polyomavirus Infections/mortality , Prognosis , Risk Assessment/methods , Skin Neoplasms/mortality , Tumor Virus Infections/immunologyABSTRACT
Hand dermatitis (HD) is usually due to a combination of various interacting factors. It involves significant impairment of the quality of life with psychological and socioeconomic impact. A therapeutic education program in HD.was elaborated by 19 health professionals (dermatologists, occupational clinical physicians, nurses, psychologists, environmental medical advisor) with experience in therapeutic education or skills in HD, according to the recommendations of Haute Autorité de Santé. The program includes an individual medical consultation to perform educational diagnostic, two collective workshops and a medical evaluation consult. Two group workshops "the disease, irritant factors and its treatments" and "the experiences and feelings" were elaborated with learning objectives and educative tools. Different scores were proposed to evaluate the program and acquired skills. Therapeutic education is an efficient way to help patients to adopt skin protection measures essential to healing. We propose a guideline of therapeutic education in HD including skills and educative tools and intended for health professionals to serve as working basis.
Subject(s)
Hand Dermatoses/therapy , Patient Education as Topic , Allergens/adverse effects , Appointments and Schedules , Chronic Disease , Dermatologic Agents/therapeutic use , Gloves, Protective , Hand Dermatoses/diagnosis , Hand Dermatoses/prevention & control , Hand Dermatoses/psychology , Hand Disinfection , Health Behavior , Humans , Irritants/adverse effects , Patient Care Team , Patient Compliance , Practice Guidelines as Topic , Surveys and QuestionnairesABSTRACT
BACKGROUND: Merkel cell polyomavirus has been recognized to be associated with Merkel cell carcinoma (MCC), but the evolution of this cancer probably depends on various factors. Vitamin D deficiency, defined by serum 25-hydroxyvitamin D levels <50 nmol/L, seems to influence cancer behavior and progression, but has never been assessed in MCC patients. OBJECTIVES: First, to evaluate whether vitamin D deficiency was associated with tumor characteristics and prognosis in a cohort of MCC patients. Second, to assess expression of the vitamin D receptor (VDR) in MCC tumors. METHODS: Clinical findings, Merkel cell polyomavirus markers and vitamin D status were assessed in a cohort of French MCC patients. The study was limited to the 89 patients for whom the serum sample had been collected within 3 years after the diagnosis of MCC. Correlation between vitamin D deficiency and MCC characteristics and outcome were determined in regression analyses. VDR expression in MCC tumours was assessed by immunohistochemistry. RESULTS: Vitamin D deficiency was noted in 65.1% of the patients and was independently associated with greater tumor size at diagnosis (P = 0.006) and with metastasis recurrence (HR, 2.89; 95% CI, 1.03 to 8.13; P = 0.043), but not with death from MCC, although there was a trend (HR, 5.28; 95% CI, 0.75 to 36.96; P = 0.093). VDR was found to be strongly expressed in all 28 MCC tumor specimens investigated. CONCLUSION: The association between vitamin D deficiency and MCC characteristics and outcome, together with detection of the VDR in MCC cells, suggest that vitamin D could influence the biology of MCC.
Subject(s)
Carcinoma, Merkel Cell/complications , Skin Neoplasms/complications , Vitamin D Deficiency/complications , Adult , Aged , Aged, 80 and over , Carcinoma, Merkel Cell/pathology , Carcinoma, Merkel Cell/therapy , Cohort Studies , Female , Humans , Male , Middle Aged , Receptors, Calcitriol/metabolism , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Treatment Outcome , Vitamin D/blood , Vitamin D Deficiency/metabolism , Vitamin D Deficiency/pathologyABSTRACT
BACKGROUND: Psoriasis is associated with higher prevalences of cardiovascular and metabolic comorbidities in adults but the relationship of age at onset and those prevalences is unknown. OBJECTIVE: To evaluate whether the childhood onset of psoriasis (COP) is correlated with the frequency of cardiovascular and metabolic comorbidities in adulthood. METHODS: This noninterventional, cross-sectional, multicentre study of adults with psoriasis was conducted in 29 dermatology centres in France. Data on sex, age at onset of psoriasis and its clinical characteristics, and cardiovascular risk factors, including weight, body mass index, waist circumference, dyslipidaemia, diabetes, hypertension, smoking, and personal/familial major adverse cardiovascular events (MACE) were systematically recorded. RESULTS: Two thousand two hundred and one patients with psoriasis (male: 56%; mean age: 49 years; 25% with COP) were included consecutively in the study. Univariate analysis showed that COP was associated with lower frequencies of obesity, high waist circumference, diabetes, dyslipidaemia, hypertension, familial cardiovascular disease, MACE and metabolic syndrome, but more frequent active smoking. Multivariate analysis retained age as being associated with frequency of cardiovascular and metabolic comorbidities, and sex with smoking, but not age at the onset of psoriasis. Psoriasis severity was associated with higher frequencies of obesity and psoriatic arthritis. CONCLUSION: Our results showed that COP does not seem to be an additional risk factor for higher frequencies of cardiovascular and metabolic comorbidities during adulthood.
Subject(s)
Cardiovascular Diseases/complications , Metabolic Diseases/complications , Psoriasis/complications , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Infant , Male , Middle Aged , Multivariate Analysis , Risk Factors , Young AdultABSTRACT
BACKGROUND: Drug patch tests (PTs) can reproduce delayed hypersensitivity to drugs and entail a moderate re-exposure of patients to offending drugs. OBJECTIVES: To determine the value of PTs for identifying the responsible drug in severe cutaneous adverse drug reactions (SCARs) such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). METHODS: In a multicentre study, PTs were conducted on patients referred for DRESS, AGEP or SJS/TEN within 1 year of their SCAR. All drugs administered in the 2 months prior to and the week following the onset of the SCAR were tested. RESULTS: Among the 134 patients included (48 male, 86 female; mean age 51·7 years), positive drug PTs were obtained for 24 different drugs. These included positive tests for 64% (46/72) of patients with DRESS, 58% (26/45) of those with AGEP and 24% (4/17) of those with SJS/TEN, with only one relapse of AGEP. The value of PTs depended on the type of drug and the type of SCAR (e.g. carbamazepine was positive in 11/13 DRESS cases but none of the five SJS/TEN cases). PTs were frequently positive for beta lactams (22 cases), pristinamycin (11 cases) and in DRESS with pump proton inhibitors (five cases), but were usually negative for allopurinol and salazopyrin. Of 18 patients with DRESS, eight had virus reactivation and positive PTs. In DRESS, multiple drug reactivity was frequent (18% of cases), with patients remaining sensitized many years later. CONCLUSIONS: PTs are useful and safe for identifying agents inducing SCAR.
Subject(s)
Drug Eruptions/diagnosis , Acute Generalized Exanthematous Pustulosis/chemically induced , Adolescent , Adult , Aged , Aged, 80 and over , Drug Eruptions/etiology , Drug Interactions , Eosinophilia/chemically induced , Female , Humans , Male , Middle Aged , Patch Tests/adverse effects , Patch Tests/methods , Stevens-Johnson Syndrome/chemically induced , Stevens-Johnson Syndrome/etiology , Time Factors , Young AdultABSTRACT
OBJECTIVE: The management of drug-induced hypersensitivity syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS) is not codified. Demonstration of the reactivation of Herpesviruses illustrates the specific pathophysiology of this syndrome. Proposals for the management of DRESS were elaborated by the cutaneous adverse drug reaction working group of the French Society of Dermatology to help with its management. METHODS: From a review of literature and the experience of the members of this group, consensual proposals were written about diagnostic criteria, tests, treatment options, and follow-up. These proposals will need to be validated in prospective studies. RESULTS: A decisional tree of treatment options is proposed, based on the severity of visceral manifestations. The importance of a rapid withdrawal of the culprit drug and of a long-term follow-up is underlined. Treatment will be adapted to the clinicobiological status (topical corticosteroid, systemic corticosteroid, intravenous gammaglobulins, antivirals).
Subject(s)
Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/therapy , Decision Trees , Eosinophilia/chemically induced , Eosinophilia/therapy , Humans , Syndrome , Virus Activation/drug effectsABSTRACT
BACKGROUND: We report the case of a patient presenting a very painful livedo of the lower back as well as paraparesis revealing a complicated abdominal aortic aneurysm. PATIENTS AND METHODS: A 61-year-old man was referred to our emergency unit for sudden lower back pain and weakness of the lower limbs. He had a large and very painful livedo racemosa on the lower back as well as partial neurological deficit of the lower limbs. Abdominal CAT revealed a bulky thrombosed infrarenal aortic aneurysm. Despite surgery, ischaemia worsened, leading to cutaneous then muscular and visceral necrosis, followed by death. DISCUSSION: Livedo racemosa of the lower limbs may be the consequence of thrombosis or embolism resulting from an abdominal aortic aneurysm. Livedo racemosa on other skin areas is uncommon but may be due to the same physiopathology. Neurological deficit is occasionally associated with a complicated abdominal aortic aneurysm or with surgical treatment thereof. However, to our knowledge, livedo on the back associated with neurological deficit has not yet been reported. Such an association should prompt practitioners to screen for a thrombosed aortic aneurysm. Furthermore, this condition is also likely to carry a poor prognosis because of the proximal secondary location of the thrombotic phenomenon, involving the lumbar arteries, which supply the medullar, cutaneous and muscular arteries.
Subject(s)
Aortic Aneurysm, Abdominal/diagnosis , Erythema/pathology , Livedo Reticularis/pathology , Thrombosis/diagnosis , Fasciitis, Necrotizing/etiology , Humans , Lumbosacral Region , Male , Middle AgedABSTRACT
This article reminds a review of photopatch tests with detailed analysis of: (1) materials used for double patch tests, and where possible, triple copies, one of which is protected from light while the other is exposed to UVA (5mJ/cm2) and the other exposed to UVB or a total spectrum of 0.75 DEM (minimum erythematous dose), with at least two readings; (2) interpretation of results to distinguish between contact allergy, contact photoallergy and/or phototoxicity; (3) materials used for UV exposure; (4) the list of (photo)allergens used in a standard series and/or a series specifically suited to the patient as well as suppliers of such series; (5) finally, the circumstances prompting photodermatological exploration.
Subject(s)
Dermatitis, Photoallergic/diagnosis , Patch Tests/methods , Ultraviolet Rays , Allergens , HumansABSTRACT
INTRODUCTION: Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. CASE REPORT: We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present. DISCUSSION: The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.
Subject(s)
Antineoplastic Agents/adverse effects , Boronic Acids/adverse effects , Multiple Myeloma/drug therapy , Neutrophils/pathology , Pyrazines/adverse effects , Skin Diseases/chemically induced , Skin Diseases/pathology , Aged , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Boronic Acids/therapeutic use , Bortezomib , Humans , Male , Neutrophils/drug effects , Pyrazines/therapeutic use , Sweet Syndrome/chemically induced , Sweet Syndrome/pathologyABSTRACT
Sézary syndrome (SS) is a rare and aggressive cutaneous lymphoma, and its diagnosis is based both on clinical, histological and biological features. None of these criteria taken alone is specific, and the two clinical observations reported here agree with this. Peripheral blood involvement, due to the presence of a variable number of Sézary cells, has been recently fully delineated by the ISCL/EORTC international organizations, and taken into account in the diagnosis and the prognosis of this syndrome. Identification and quantification of peripheral blood Sézary cells on the blood smear is an essential criterion for the diagnosis and is sufficient when associated with relevant clinical or/and histological grounds. Flow cytometry is another tool to demonstrate Sézary cells within the peripheral blood mononuclear cells. The authors discuss about the respective advantages and limits of morphology and flow cytometry in the identification and enumeration of circulating Sézary cells. Molecular biology is helpful in peculiar situations.
Subject(s)
Neoplastic Cells, Circulating , Sezary Syndrome/blood , Sezary Syndrome/diagnosis , Skin Neoplasms/blood , Skin Neoplasms/diagnosis , Aged , Aged, 80 and over , Female , Humans , MaleABSTRACT
BACKGROUND: Cutaneous angiosarcoma is a rare aggressive vascular neoplasm with a poor prognosis, seen chiefly in elderly subjects and usually on the scalp or face. The present case is original because of its localization on the leg without any chronic lymphoedema and because of the long survival period. The treatment modalities are discussed. CASE REPORT: An 87-year-old woman presented with a rapidly growing large deep-purple ulcerated tumour on the anterior aspect of the leg. In addition, two nodules with a similar aspect appeared on the outer surface of the foot. Histological examination showed vascular channels lined with atypical cells consistent with a diagnosis of angiosarcoma. Computed tomography revealed no metastases. Amputation was performed at the thigh and there was no recurrence 30 months later. DISCUSSION: The leg is a rare site of cutaneous angiosarcoma. Treatment usually consists of surgical excision with wide margins followed by radiotherapy, but in some cases amputation is unavoidable.
Subject(s)
Hemangiosarcoma , Leg , Skin Neoplasms , Aged, 80 and over , Amputation, Surgical , Female , Follow-Up Studies , Hemangiosarcoma/diagnostic imaging , Hemangiosarcoma/pathology , Hemangiosarcoma/surgery , Humans , Leg/surgery , Skin/pathology , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Time Factors , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Basal cell carcinoma is a very common form of skin cancer but its occurrence on the toenail unit is very rare. We report such a case of basal cell carcinoma localized on the proximal nail fold of the right hallux. CASE REPORT: A 67-year-old woman had a 7-year history of a non-healing ulcer on the proximal nail fold of the right hallux after antibiotics and treatment of her onychomycosis. Bowen's disease and squamous cell carcinoma were suspected. Histopathologic examination of a biopsy specimen revealed infiltrative basal cell carcinoma. The lesion was surgically excised with a 0.5 cm margin and the defect was repaired by full-thickness skin graft with good functional and cosmetic results. DISCUSSION: Basal cell carcinoma is the most common skin cancer but its localization on fingers, toes and nail units is very rare. Only six cases of basal cell carcinoma on the toe nail unit have been reported to date in the literature. Clinical aspects often mimic benign processes, resulting in misdiagnosis. Treatment requires simple excision or Mohs micrographic surgery. Our case emphasizes the value of biopsy for all nail unit lesions of atypical appearance, course or therapeutic response.